CAPTRUST Financial Advisors
KRYS icon

CAPTRUST Financial Advisors’s Krystal Biotech KRYS Stock Holding History

CAPTRUST Financial Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$550K Buy
1,654
+206
+14% +$71.4K ﹤0.01% 2149
2026
Q2 		$538K Buy
1,448
+269
+23% +$80.4K ﹤0.01% 2133
2026
Q1 		$305K Buy
1,179
+4
+0.3% +$1.06K ﹤0.01% 2374
2025
Q4 		$290K Buy
+1,175
New +$247K ﹤0.01% 2277
2022
Q3 		– Sell
-155
Closed -$10K – 3127
2022
Q2 		$10K Buy
155
+102
+192% +$6.34K ﹤0.01% 3748
2022
Q1 		$4K Sell
53
-16
-23% -$999 ﹤0.01% 4250
2021
Q4 		$5K Buy
+69
New +$4.02K ﹤0.01% 4073

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

CAPTRUST Financial Advisors's KRYS Position: Q3 2026 in Review

CAPTRUST Financial Advisors increased its Krystal Biotech (KRYS) stake by 14% in Q3 2026, buying an estimated $71.4K and bringing the position to 1,654 shares worth $550K. The position accounts for ﹤0.01% of the portfolio, ranked #2149.

CAPTRUST Financial Advisors first reported a position in KRYS in Q4 2021 and has held it in 7 quarters since. 353 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • CAPTRUST Financial Advisors held 1,654 shares of Krystal Biotech worth $550K as of Q3 2026.
  • CAPTRUST Financial Advisors bought 206 Krystal Biotech shares in Q3 2026, an estimated $71.4K.
  • Krystal Biotech made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q3 2026, its #2149 holding.
  • CAPTRUST Financial Advisors first reported a position in Krystal Biotech in Q4 2021 and has held it in 7 quarters since.
  • 353 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.